Skip to content
October 06, 2022

Equity.Guru

Investment information for the new generation

Pharmaceuticals

Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company that has been making big moves on the charts. The company is not a biotech company. They do not do research…
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company. They are not biotech. There is no research and development here. Medexus is all about sales and marketing, bringing over drugs…
Specialty pharma company Medexus Pharmaceuticals (MDP.TO) provided an update on the Treosulfan NDA resubmission and provided a business update. On September 16th 2022, Medexus was informed by Medac, licensor…
Big pharma firms like Abbvie can offer incredible product growth potential to investors, but they also saddle shareholders with tremendous risk in terms of regulatory approval and capital cost….
Medexus Pharmaceuticals (MDP.TO) is a specialty pharma company whose stock is on fire! The stock rallied 34% from its opening price to its highs last week. And it has…
Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company focused on acquiring and distributing innovative rate disease treatment solutions, announced its financial results for Q1 2023. The company reported a…
Medexus (MDP.T), a Canadian-based specialty pharma firm focused on acquiring and distributing innovative rare disease treatment solutions in North America, announced today that its strategic partner, medac, had resubmitted…
Last year Big Pharma unleashed 1,500 lobbyists to Washington, DC, who then cut cheques for $177 million to keep drug costs high. The lobbyists deserve bonuses. The average U.S….
Repare Therapeutics (RPTX) is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its…
Immunoprecise Antibodies (IPA.V) subsidiary Biostrand and VLAIO—Flanders Innovation and Entrepreneurship—the research fund of the Flemish regional government in Belgium—have greed on a 460,000-euro round of grant financing. This award…